Literature DB >> 85719

In vitro synthesis of infectious transforming DNA by the avian sarcoma virus reverse transcriptase.

C H Clayman, E Mosharrafa, A J Faras.   

Abstract

Infectious DNA molecules, capable of transforming chicken embryo fibroblasts, can be synthesized by the Rous sarcoma virus-associated reverse transcriptase in vitro. The optimal enzymatic conditions employed for infectious DNA synthesis also facilitate maximum synthesis of genome length DNA. Analysis of the DNA product synthesized by detergent-disrupted Rous sarcoma virus under these conditions indicates that DNA complementary to viral RNA (minus-strand DNA) is genome length in size, whereas DNA complementary to genome length minus-strand DNA (plus-strand DNA) appears as subgenomic-length molecules ranging between 300 and 3,500 nucleotides in length. These features of the DNA product synthesized by the Rous sarcoma virus reverse transcriptase in vitro are similar to those identified in the cytoplasm of cells shortly after infection and lend credence to studies of the mechanism of reverse transcription in vitro and their significance to proviral DNA synthesis in vivo.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 85719      PMCID: PMC353108          DOI: 10.1128/JVI.29.1.242-249.1979

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Partially single-stranded form of free Moloney viral DNA.

Authors:  A M Gianni; R A Weinberg
Journal:  Nature       Date:  1975-06-19       Impact factor: 49.962

2.  Murine leukemia virus: detection of unintegrated double-stranded DNA forms of the provirus.

Authors:  A M Gianni; D Smotkin; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1975-02       Impact factor: 11.205

3.  Use of alkaline sucrose gradients in a zonal rotor to detect integrated and unintegrated avian sarcoma virus-specific DNA in cells.

Authors:  H E Varmus; S Heasley; J Linn; K Wheeler
Journal:  J Virol       Date:  1976-05       Impact factor: 5.103

4.  Infectivity of visna virus DNA.

Authors:  A T Haase; B L Traynor; P E Ventura; D W Alling
Journal:  Virology       Date:  1976-03       Impact factor: 3.616

5.  In vitro synthesis of full-length DNA transcripts of Rous sarcoma virus RNA by viral DNA polymerase.

Authors:  R P Junghans; P H Duesberg; C A Knight
Journal:  Proc Natl Acad Sci U S A       Date:  1975-12       Impact factor: 11.205

6.  Orientation of the complementary strands of polyoma virus DNA with respect to the DNA physical map.

Authors:  R Kamen; J Sedat; E Ziff
Journal:  J Virol       Date:  1975-01       Impact factor: 5.103

7.  Post-transcriptional control of avian oncornavirus transforming gene sequences in mammalian cells.

Authors:  R A Krzyzek; A F Lau; A J Faras; D H Spector
Journal:  Nature       Date:  1977-09-08       Impact factor: 49.962

8.  Covalently closed circular DNA of avian sarcoma virus: purification from nuclei of infected quail tumor cells and measurement by electron microscopy and gel electrophoresis.

Authors:  R V Guntaka; O C Richards; P R Shank; H J Kung; N Davidson
Journal:  J Mol Biol       Date:  1976-09-15       Impact factor: 5.469

9.  Virus-specific DNA in the cytoplasm of avian sarcoma virus-infected cells is a precursor to covalently closed circular viral DNA in the nucleus.

Authors:  P R Shank; H E Varmus
Journal:  J Virol       Date:  1978-01       Impact factor: 5.103

10.  In vitro synthesis and characterisation of full- and half-genome length complementary DNA from avian oncoviruses.

Authors:  M M Lai; S S Hu
Journal:  Nature       Date:  1978-02-02       Impact factor: 49.962

View more
  10 in total

1.  Viral genome RNA serves as messenger early in the infectious cycle of murine leukemia virus.

Authors:  R Shurtz; S Dolev; M Aboud; S Salzberg
Journal:  J Virol       Date:  1979-09       Impact factor: 5.103

2.  Effect of viral RNase H on the avian sarcoma viral genome during early transcription in vitro.

Authors:  R Friedrich; K Moelling
Journal:  J Virol       Date:  1979-09       Impact factor: 5.103

3.  Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors.

Authors:  W A O'Brien; A Namazi; H Kalhor; S H Mao; J A Zack; I S Chen
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

4.  Two species of full-length cDNA are synthesized in high yield by melittin-treated avian retrovirus particles.

Authors:  L R Boone; A Skalka
Journal:  Proc Natl Acad Sci U S A       Date:  1980-02       Impact factor: 11.205

5.  Direct proof of the 5' to 3' transcriptional jump during reverse transcription of the avian retrovirus genome by DNA sequencing.

Authors:  C A Omer; J T Parsons; A J Faras
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

6.  Viral DNA synthesized in vitro by avian retrovirus particles permeabilized with melittin. I. Kinetics of synthesis and size of minus- and plus-strand transcripts.

Authors:  L R Boone; A M Skalka
Journal:  J Virol       Date:  1981-01       Impact factor: 5.103

7.  Synthesis of murine leukemia viral DNA in vitro: evidence for plus-strand DNA synthesis at both ends of the genome.

Authors:  L DesGroseillers; E Rassart; M Zollinger; P Jolicoeur
Journal:  J Virol       Date:  1982-04       Impact factor: 5.103

8.  Equine infectious anemia virus and human immunodeficiency virus DNA synthesis in vitro: characterization of the endogenous reverse transcriptase reaction.

Authors:  K Borroto-Esoda; L R Boone
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

9.  Identification of a RNA polymerase II initiation site in the long terminal repeat of Moloney murine leukemia viral DNA.

Authors:  S A Fuhrman; C Van Beveren; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1981-09       Impact factor: 11.205

10.  Analysis of avian myeloblastosis viral RNA and in vitro synthesis of proviral DNA.

Authors:  R A Schulz; J G Chirikjian; T S Papas
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.